Seven biopharma companies are under new leadership. This week’s Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island.
Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr, a potential treatment for complicated urinary tract infections.
For companies that are still trying to determine what digital transformation should look like within their operations, they should look to Ireland where companies are using new and disruptive technology to transform product innovation, manufacturing operations and sustainability efforts in life sciences.
Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world’s largest pharmaceutical market.
A 3-judge panel questioned the legitimacy of Johnson & Johnson’s plan to form a subsidiary company with the purpose of absorbing legal liabilities from talc-related lawsuits.
Moderna Inc.Chief Medical Officer Paul Burton said on Wednesday the company is “eager” to collaborate with China on supplying its mRNA-based COVID-19 vaccines to the country.
CVS Health Corp. and Walmart Inc. have agreed to pay $147.5 million to settle West Virginia’s claims over their alleged roles in the state’s opioid crisis, state attorney general Patrick Morrisey said Tuesday.
The U.S. Food and Drug Administration on Tuesday warned that certain types of insulin pump systems manufactured by Medtronic were vulnerable to cyberattacks and that hackers could potentially hamper insulin delivery by accessing the device.
Six months after its official launch by Flagship Ventures, Massachusetts-based Vesalius Therapeutics is laying off 43% of its staff. With a current headcount of 67, the company is slashing 29 jobs.